ClinicalTrials.gg
RecruitingNCT07554469FINEXPLORERUpdated Oct 14, 2026

An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk Score

An observational study in Chronic Kidney Disease and Type 2 Diabetes Mellitus, sponsored by Bayer. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Bayer · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Oct 14, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Renal Insufficiency, Chronic by Bayer — 4 open to participants now, 8 under way, 2 of them phase 3. Renal Insufficiency, Chronic · Bayer.

Planned enrollment
15th of 17
500 · median 4,613
Started
2026
with 3 others
Observational
17 of 49
3 open now
Registered
47th of 49
by date

Among the 49 studies in Renal Insufficiency, Chronic by Bayer, this one is the 15th largest by planned enrollment of the 17 observational ones that give a count, is one of 4 that started in 2026, is one of 17 observational ones, and was the 47th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

4 of the 49 studies in Renal Insufficiency, Chronic by Bayer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Renal Insufficiency, Chronic by Bayer, or all of them as a file.
02

Study summary

This is a prospective observational study in which data from people with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) who will be receiving finerenone are collected and analyzed.

Chronic kidney disease (CKD) is common in people with type 2 diabetes. It can get worse over time and may lead to kidney failure and heart problems. Doctors often track kidney health using blood and urine tests, including the estimated glomerular filtration rate (eGFR) and the urine albumin-to-creatinine ratio (UACR). There are also tools that combine routine laboratory test results to estimate a person's risk of their kidney disease getting worse. One of these tools is called the Klinrisk model.

The study drug, finerenone, is already approved for doctors to prescribe to patients with CKD associated with T2D and albumin in the urine.

Finerenone works by blocking the mineralocorticoid receptor, a protein involved in inflammation and scarring in the kidneys and heart. The study drug, finerenone, is a non-steroidal mineralocorticoid receptor modulator that aims to reduce harmful kidney and heart changes.

The main purpose of this study is to determine whether the Klinrisk score improves after 2 years of treatment with finerenone in adults with CKD associated with T2D who are treated in routine care. To achieve this, researchers will collect data on:

  • Clinical characteristics of participants, including their medical history related to CKD and T2D.
  • Variables used to assess the CKD progression, such as eGFR, UACR, and Blood Urea Nitrogen (BUN).
  • Participants' glucose, hemoglobin and potassium levels.

The study will also monitor any medical problems (known as adverse events) that participants may experience during the study. All adverse events will be recorded, regardless of whether they are related to the treatment.

Data will be collected from April 2026 to April 2029 and will cover a period of up to 24 months per participant. Data collection will occur over 5 visits that coincide with routine clinical care: inclusion, follow-up visits at 6, 12, and 18 months (±1 month), and a final visit at 24 months (±1 month).

03

Conditions studied

  • Chronic Kidney Disease
  • Type 2 Diabetes Mellitus

Keywords

  • Finerenone
  • Chronic Kidney Disease
  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants with a diagnosed of CKD and T2D will be enrolled after the decision for treatment with finerenone has been made by the treating physician.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who sign the written to participate in the study.
  • Men or women aged ≥18 years.
  • Patients with CKD associated with type 2 diabetes and albuminuria (UACR >30 mg/g).
  • Patients initiated on finerenone in routine clinical practice, according to the Summary of Product Characteristics (SmPC), within the 2 months prior to inclusion.

Exclusion criteria

Exclusion Criteria:

  • \< 25 mL/min/1.73 m².
  • Severe hepatic impairment.
  • Clinical diagnosis of chronic heart failure with reduced (HFrEF) and persistent symptoms.
  • Confirmed significant non-diabetic renal disease, including renal artery stenosis.
  • Uncontrolled arterial hypertension (mean sitting systolic blood pressure [SBP] ≥160 mmHg or diastolic blood pressure [DBP] ≥100 mmHg at inclusion).
  • Concomitant therapy with eplerenone, spironolactone, any renin inhibitor, or a potassium-sparing diuretic that has not been discontinued at least 4 weeks prior to inclusion.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Participants diagnosed with CKD and T2D

    Participants who are newly prescribed finerenone under routine treatment conditions.

    Drug: Finerenone (Kerendia, BAY94-8862)

Interventions

  • DrugFinerenoneStudies of FinerenoneFinerenone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Decision will be taken by the treating physician to initiate treatment with finerenone.

06

What researchers measure

Primary outcomes

  1. Percentage of patients who show an improvement in the Klinrisk model score after 24 months of treatment with finerenone.

    Time frame: Up to 24 months from the beginning of treatment with finerenone.

Secondary outcomes

  1. Percentage of patients who show an improvement in the Klinrisk model score after 12 months of treatment with finerenone.

    Time frame: Up to 12 months from the beginning of treatment with finerenone.

  2. Cumulative incidence (%) of the composite outcome of kidney failure, a sustained decrease of at least 40% in the eGFR from the beginning of treatment with finerenone (index date), or death from renal causes.

    Time frame: Up to 24 months from the beginning of treatment with finerenone.

  3. Time to the composite endpoint of renal outcomes.

    Composite outcome of kidney failure, a sustained decrease of at least 40% in the eGFR from the beginning of treatment with finerenone (index date), or death from renal causes.

    Time frame: Up to 24 months from the beginning of treatment with finerenone.

  4. Cumulative incidence (%) for kidney failure.

    Time frame: Up to 24 months from the beginning of treatment with finerenone.

  5. Cumulative incidence (%) for sustained decrease in eGFR to <15 mL/min/1.73 m2 maintained for at least 4 weeks.

    eGFR = estimated glomerular filtration rate.

    Time frame: Up to 24 months from the beginning of treatment with finerenone.

  6. Cumulative incidence (%) for sustained ≥40% eGFR decline from baseline maintained for at least 4 weeks.

    Time frame: Up to 24 months from the beginning of treatment with finerenone.

  7. Cumulative incidence (%) of KRT.

    KRT = kidney replacement therapy.

    Time frame: Up to 24 months from the beginning of treatment with finerenone.

  8. Cumulative incidence (%) of death from renal causes.

    Time frame: Up to 24 months from the beginning of treatment with finerenone.

  9. Change in UACR at months 6, 12, 18 and 24 (> 30%, 40% or >50%)

    UACR = urinary albumin-to-creatinine ratio

    Time frame: At months 6, 12, 18 and 24.

  10. Change in eGFR chronic slope at months 6, 12, 18 and 24.

    Time frame: At months 6, 12, 18 and 24.

  11. Levels of NT-proBNP values.

    Time frame: Up to 24 months from the beginning of treatment with finerenone.

  12. Cumulative incidence (%) of the composite outcome of death from CV causes, nonfatal myocardial infarction, nonfatal stroke or hospitalization for heart failure.

    Time frame: Up to 24 months from the beginning of treatment with finerenone.

  13. Cumulative incidence (%) of death from CV causes.

    Time frame: Up to 24 months from the beginning of treatment with finerenone.

  14. Cumulative incidence (%) of nonfatal myocardial infarction.

    Time frame: Up to 24 months from the beginning of treatment with finerenone.

  15. Cumulative incidence (%) of nonfatal stroke.

    Time frame: Up to 24 months from the beginning of treatment with finerenone.

  16. Cumulative incidence (%) of hospitalizations for heart failure.

    Time frame: Up to 24 months from the beginning of treatment with finerenone.

  17. Incidence rate of death from CV causes.

    Time frame: Up to 24 months from the beginning of treatment with finerenone.

  18. Incidence rate of nonfatal myocardial infarction.

    Time frame: Up to 24 months from the beginning of treatment with finerenone.

  19. Incidence rate of nonfatal stroke.

    Time frame: Up to 24 months from the beginning of treatment with finerenone.

  20. Incidence rate of hospitalization for heart failure.

    Time frame: Up to 24 months from the beginning of treatment with finerenone.

  21. Number of adverse events (AEs) that occur during the study period.

    Time frame: Up to 30 days after the final treatment with finerenone.

  22. Number of discontinuations of finerenone for AEs.

    Time frame: Up to 24 months from the beginning of treatment with finerenone.

  23. Number of hospitalizations for AEs.

    Time frame: Up to 24 months from the beginning of treatment with finerenone.

  24. Percentage of patients with hypokalemia, normokalemia and hyperkalemia.

    Time frame: Up to 24 months from the beginning of treatment with finerenone.

  25. Percentage of patients who maintain normokalemia over the entire follow-up.

    This endpoint will be analysed in patients with normokalemia at the start of finerenone.

    Time frame: Up to 24 months from the beginning of treatment with finerenone.

  26. Incidence of acute kidney injury (AKI) requiring hospitalization.

    Time frame: Up to 24 months from the beginning of treatment with finerenone.

07

Study locations

1 of 1 sites recruiting
  • Many locations
    Many Locations, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access. As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2029, 36 months after the start.

Of 51 industry-sponsored observational studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 51. This study's planned 36 months is above that.

Counting every sponsor, half of 327 studies reached it within 45 months; a quarter within 22 and three quarters within 191.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Apr 2029 → May 2029 and completion Apr 2029 → May 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2026
First posted
Apr 28, 2026
StartActual
May 26, 2026
Primary completionEst.
May 31, 2029was Apr 2029
CompletionEst.
May 31, 2029was Apr 2029
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Many locations · Many Locations, Spain
Show 1 removed
  • Many locations · Multiple Locations, Spain
Oct 14, 2026
Primary completion
Apr 30, 2029→May 31, 2029
Oct 14, 2026
Study completion
Apr 30, 2029→May 31, 2029
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    1 site added, 1 site removed
    Show site
    • Many locations · Many Locations, Spain
    Show 1 removed
    • Many locations · Multiple Locations, Spain
    Primary completion Apr 30, 2029→May 31, 2029
    Study completion Apr 30, 2029→May 31, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07554469
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Apr 28, 2026
Start date
May 26, 2026
Primary completion
May 31, 2029 (estimated)
Completion
May 31, 2029 (estimated)
Last update
Oct 14, 2026

Study contacts

Bayer Clinical Trials Contact
Contact
clinical-trials-contact@bayer.com
(+)1-888-84 22937

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion